NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
3
Frequently Asked Questions
What is Market Cap of NeuBase Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. NeuBase Therapeutics Inc market cap is $10.07M.
What is the 52-week high for NeuBase Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. NeuBase Therapeutics Inc 52 week high is $6.28 as of October 25, 2025.
What is the 52-week low for NeuBase Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. NeuBase Therapeutics Inc 52 week low is $1.58 as of October 25, 2025.
What is the PE ratio of NeuBase Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. NeuBase Therapeutics Inc’s P/E ratio is None.
What is the Price-to-Book ratio of NeuBase Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. NeuBase Therapeutics Inc P/B ratio is 1.1182.
What is NeuBase Therapeutics Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. NeuBase Therapeutics Inc's EBITDA is -1.25.
What is the 50-day moving average of NeuBase Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. NeuBase Therapeutics Inc 50-day moving average is $3.42.
How many employess does NeuBase Therapeutics Inc has?
